Crimson Publishers Publish With Us Reprints e-Books Video articles


Advances in Complementary & Alternative medicine

The Winner of the Contest to Eradicate Cancer Stem Cells Wins the Contest of Cancer Therapies: The Winner is Cell Differentiation Agent Formulations

  • Open or Close Ming C Liau1* and John P Fruehauf2

    1 CDA Therapeutics, USA

    2 Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, USA

    *Corresponding author: Ming C Liau, CDA Therapeutics, 2384 Tubbs Dr, Tustin, CA, USA

Submission: January 08, 2020; Published: January 10, 2020

DOI: 10.31031/ACAM.2019.05.000620

ISSN: 2637-7802
Volume5 Issue4


It has been widely accepted that most human cancers had a small subpopulation of cancer stem cells (CSCs) which were closely related to progenitor stem cells (PSCs) based on cell features and biological missions. These cells express ATP binding cassette drug pump that can effectively exclude toxic materials and have activation of anti-apoptosis programs that negate the pro-apoptotic signals activated by DNA damaging agents [1-4]. Thus, these cells are resistant to cytotoxic drugs and radiation. These cells normally reside in acidic and hypoxic microenvironment hard to reach by the blood stream. Like PSCs, CSCs may remain dormant unless situations arise that stimulate their recruitment, such as cytotoxic chemotherapy.

Get access to the full text of this article